Electronic drug delivery systems ensure precise and controlled administration of medications. These innovative systems enhance treatment efficacy, improve patient adherence, and offer personalized dosage regimens. With features such as automated delivery and real-time monitoring, they provide healthcare professionals with valuable insights, promoting better disease management. It contributes to improved patient outcomes, making drug administration more accurate, convenient, and tailored to individual needs.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-electronic-drug-delivery-systems-market
Data Bridge Market Research analyses the Global Electronic Drug Delivery Systems Market which was USD 16,139.89 million in 2022, is expected to reach up to USD 17,576.34 million by 2030, and is expected to undergo a CAGR of 8.9% during the forecast period 2023-2030. The rapid progress in microtechnology serves as a key driver for the market. This advancement empowers the creation of highly sophisticated devices capable of precise dosage control, usage monitoring, and seamless connectivity with healthcare providers via mobile apps and cloud platforms.
Key Findings of the Study
Rising chronic diseases are expected to drive the market's growth rate
The electronic drug delivery systems market is driven by the growing burden of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions. This surge in prevalence creates a demand for advanced drug delivery systems that can offer continuous monitoring and precise medication delivery. Electronic devices, such as smart pumps and wearable technologies, enable real-time monitoring of patient's health metrics and facilitate targeted drug administration. The market is propelled by the need for innovative solutions that address the complexities of chronic diseases, offering patients more effective and personalized therapeutic interventions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
AstraZeneca (U.K.), Amgen Inc. (U.S.), Ypsomed AG (Switzerland), Merck KGaA (U.S.), Bayer AG (Germany), Nemera (France), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceuticals USA, Inc. (U.S.), AptarGroup, Inc. (U.S.), Novo Nordisk A/S. (Denmark), ViCentra B.V. (Netherlands), Medtronic (U.S.), United Therapeutics Corporation (U.S.), Companion Medical (U.S.), Tandem Diabetes Care, Inc. (U.S.), Debiotech S.A. (Switzerland), Canè S.p.A (Italy), Insulet Corporation (U.S.), BD (U.S.), and B. Braun Melsungen AG (Germany)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, and end-user.
- On the basis of type, the global electronic drug delivery systems market is segmented into electronic infusion pumps, electronic injection pens, electronic auto-injectors, electronic inhalers, electronic capsules, and others
- On the basis of component, the global electronic drug delivery systems market is segmented into sensors, wireless communicator and antennas, micro pumps and flow regulators, drug reservoir, microcontroller, and others
- On the basis of connectivity, the global electronic drug delivery systems market is segmented into bluetooth low energy (ble), Wi-Fi, ethernet, Nb-IoT, and others
- On the basis of system type, the global electronic drug delivery systems market is segmented into battery-powered systems, and rechargeable systems
- On the basis of application, the global electronic drug delivery systems market is segmented into diabetes, asthma and chronic obstructive pulmonary disease (COPD), multiple sclerosis, growth hormone therapy, immunodeficiency disease, cardiovascular disease, thalassemia, and others
- On the basis of end-user, the global electronic drug delivery systems market is segmented into home healthcare, hospitals, clinics, ambulatory centers, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major global electronic drug delivery systems market players in global electronic drug delivery systems market are AstraZeneca (U.K.), Amgen Inc. (U.S.), Ypsomed AG (Switzerland), Merck KGaA (U.S.), Bayer AG (Germany), Nemera (France), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceuticals USA, Inc. (U.S.), AptarGroup, Inc. (U.S.)
Market Developments
- In 2022, Gufic Biosciences Ltd made a significant impact in India by introducing a groundbreaking drug delivery system, the Dual Chamber Bags, at affordable prices. This move marked a notable step towards enhancing accessibility to advanced medical technologies within the country
- In 2022, Takeda achieved a milestone by securing approval from the US FDA for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). This approval highlights the effectiveness of the drug in preventing attacks of hereditary angioedema (HAE) and provides a convenient and user-friendly solution for adult and pediatric patients aged 12 and older
- In 2021, Merck entered into a strategic collaboration with B. Braun, focusing on the development of bioelectronic devices for drug delivery. This collaboration underscores the commitment to advancing innovative solutions in drug administration, potentially revolutionizing the way drugs are delivered and managed
- In 2020, Medtronic plc introduced Efficio, a cloud-based data management software designed for use with the SynchroMed II intrathecal drug delivery system. This development aimed to enhance the efficiency of clinicians in managing targeted drug delivery pump practices, particularly for patients dealing with chronic pain, cancer pain, and severe spasticity.
Regional Analysis
Geographically, the countries covered in the global electronic drug delivery systems market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
As per Data Bridge Market Research analysis:
North America is the dominant region in global electronic drug delivery systems market during the forecast period 2023-2030
North America dominates the global electronic drug delivery systems market due to widespread adoption of electronic infusion pumps in the region. Electronic infusion pumps, devices delivering fluids and medications with precision, have seen a substantial increase in usage. The advanced healthcare infrastructure, higher prevalence of chronic diseases, and a propensity for adopting innovative medical technologies contribute to North America's leadership in this market.
Asia-Pacific is estimated to be the fastest-growing region in the global electronic drug delivery systems market for the forecast period 2023-2030
The Asia-Pacific region is forecasted to experience the highest growth rate in the market from 2023 to 2030. This is primarily attributed to a rising incidence of asthma and heart disease in the region, prompting a demand for advanced drug delivery systems. The concurrent development and sophistication of the pharmaceutical industry in Asia-Pacific contribute to this growth, as electronic drug delivery systems align with the industry's pursuit of more effective and patient-friendly treatment options.
For more detailed information about the global electronic drug delivery systems market report, click here – https://www.databridgemarketresearch.com/reports/global-electronic-drug-delivery-systems-market
